Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
36.37 CHF | -2.79% | -.--% | +3.34% |
06-25 | German Stocks Fall Tuesday | DJ |
06-25 | Eckert & Ziegler Unit Gets 'Encouraging' Feedback from US FDA for Lead Diagnostic | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.1 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.3 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Office Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.34% | 1.01B | - | ||
-11.12% | 4.33B | B | ||
+2.31% | 3.21B | - | ||
+16.32% | 2.26B | - | ||
+8.93% | 946M | - | ||
-41.40% | 890M | - | ||
-59.03% | 645M | - | ||
-35.65% | 629M | - | ||
-29.46% | 626M | - | - | |
-36.83% | 560M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EUZ Stock
- EUZ Stock
- Ratings Eckert & Ziegler SE